Can we detect cancer before it’s too late?

As a child, Angie Belcher spent hours in libraries near her Texas home, following her curiosity wherever it led.

It eventually carried her into a career that defies easy labels. “Today, I can call myself a chemist, an engineer, a biological engineer,” the MIT professor says. “But I feel that I’m primarily an inventor.”

For many years, Angie was drawn to how nature builds things. As an undergraduate, she studied materials like seashells, which are far stronger than the minerals they’re made from. Later, as a young scientist, she began engineering viruses to act as microscopic builders: By tweaking their DNA, she could get them to assemble tiny structures used in batteries and electronics.

But starting around 2010, her work took a more personal turn.

Cancer had threaded through her life. Her mother fought it. Her grandmother died from it. Two close colleagues, both brilliant scientists, were lost to ovarian cancer. Angie found herself confronting a painful reality: Even in Boston, one of the world’s leading medical hubs, these women could not be saved.

Ovarian cancer, in particular, seemed to expose a failure not of treatment, but of timing. It is notoriously hard to detect early. By the time symptoms appear, the disease has often spread.

So Angie began to ask a different question — not how to treat cancer, but how to detect it sooner. “A lot of what I do is to try to address these limitations on why we can’t find ovarian cancer at early stages, when you can remove it before it metastasizes,” she says.

Staggered by medicine’s struggle to detect a millimeter-scale tumor inside the human body, she turned back to what she knew best: engineering at the nanoscale.

Working with MIT colleagues Sangeeta Bhatia and Paula Hammond, she began developing imaging tools that could reveal what doctors currently miss. One approach uses engineered viruses paired with glowing materials. These particles move through the body, attach to tumors, and light them up, helping surgeons see cancers that would otherwise remain hidden.

Her lab also developed imaging systems capable of detecting tumors as small as half a millimeter — tiny enough to catch cancer at its earliest stages. In animal studies, these tools didn’t just find tumors; they extended survival, increasing median lifespan by about 40 percent.

The implications were profound. Detection, not just treatment, could change outcomes.

And the biology of ovarian cancer itself offered a clue. Researchers now understand that in many cases, the disease begins not in the ovaries, but in the fallopian tubes — where precancerous lesions can linger, hidden, before spreading. If those lesions could be found early, intervention could come before the disease turns deadly.

Angie’s team is working toward that goal. Together with scientists at Johns Hopkins University, Angie is developing ways to scan entire fallopian tubes, not just small samples, to catch the earliest signs of disease and help women manage their risk of developing ovarian cancer. At the same time, her lab is designing tiny particles that can both find and fight cancer, delivering drugs directly to tumors while also helping doctors see where the disease is. The team has also mounted an initiative — the Outsmart Ovarian Cancer Collaborative — to educate patients and doctors about the disease.

Through all this, Angie’s ambition is clear: to make early detection routine, accessible, and reliable — so ovarian cancer is no longer found too late. She believes that could happen within the next decade.

Because at its core, Angie Belcher’s work is about time.

“Part of the meaning of life is helping other people enjoy the passage of time,” she says. “We can do that by solving big problems — like finding ovarian cancer earlier — so people have more time with their families.”